SignalCorporate
Amgen Inc (AMGN) (Q3 2026) Earnings Call Highlights: Revenue Up 8% to $10. ...
Amgen Q3 2026 revenue rose 8% to $10 billion, a key earnings catalyst.
Context
What happened: Amgen reported Q3 2026 total revenues up 8% year over year to $10.4 billion and raised its full-year 2026 revenue and non-GAAP EPS guidance.
Key numbers: Revenue $10.4 billion, up 8%. Non-GAAP operating margin 47%. Free cash flow $3.7 billion. Dividend $2.52 per share, up 6%.
Why it matters: Six key growth drivers rose 27% and represented over 70% of product sales, and management said it anticipates no operating margin step-down in 2027. MariTide Phase 3 data readouts remain pending, and the regulatory path for DAZODALIBEP in Sjogren's disease remains unclear.
Market: -0.9% today ($461.26), +42.8% YTD, 0.8x vol — as of 10:30 UTC
Verified: Q3_2026 (Nov 3) EPS $6.45 vs $5.78 est, +11.5% beat; next print ~Feb 2
Coverage: 3 outlets in 24h
What changed
Amgen reported Q3 2026 total revenues up 8% year over year to $10.4 billion and raised its full-year 2026 revenue and non-GAAP EPS guidance.
Why it matters
Six key growth drivers rose 27% and represented over 70% of product sales, and management said it anticipates no operating margin step-down in 2027. MariTide Phase 3 data readouts remain pending, and the regulatory path for DAZODALIBEP in Sjogren's disease remains unclear.
Market: -0.9% today ($461.26), +42.8% YTD, 0.8x vol — as of 10:30 UTC
Verified: Q3_2026 (Nov 3) EPS $6.45 vs $5.78 est, +11.5% beat; next print ~Feb 2